论文部分内容阅读
目的探讨肺表面活性物质珂立苏联合呼吸机治疗新生儿呼吸窘迫综合征的临床疗效。方法将2011年1月-2012年12月我院收治的呼吸窘迫新生儿78例随机分为两组各39例,实验组采用NCPAP呼吸机支持治疗,并注射肺表面活性物质;对照组只给予NCPAP呼吸机支持治疗。观察比较两组患儿通气前、通气后4h与12h时动脉血气分析,以及氧疗时间、机械通气时间、住院时间等。结果两组患儿在通气前后血气分析指标改变组内差异无统计学意义(P>0.05)。实验组在通气后4h、12h时的血气分析较对照组有明显改变(P<0.05);实验组在氧疗时间、机械通气时间与住院时间上较对照组明显缩短,且治疗效果更明显(P<0.05)。结论肺表面活性物质珂立苏联合呼吸机治疗新生儿呼吸窘迫综合征疗效良好,值得临床推广。
Objective To investigate the clinical efficacy of pulmonary surfactant Curr combined with ventilator in the treatment of neonatal respiratory distress syndrome. Methods 78 cases of neonatal respiratory distress admitted to our hospital from January 2011 to December 2012 were randomly divided into two groups of 39 cases. The experimental group was treated with NCPAP ventilator and the pulmonary surfactant was injected. The control group was given only NCPAP ventilator support treatment. Two groups of children before and after ventilation, 4h and 12h after ventilation, arterial blood gas analysis, and oxygen therapy time, mechanical ventilation time, hospital stay and so on. Results There was no significant difference between the two groups in the change of blood gas analysis indexes before and after ventilation (P> 0.05). Compared with the control group, the blood gas analysis of the experimental group at 4h and 12h after ventilation significantly changed (P <0.05); the oxygen therapy time, mechanical ventilation time and hospitalization time in the experimental group were significantly shorter than those in the control group, and the treatment effect was more obvious P <0.05). Conclusion Pulmonary surfactant Curr combined with ventilator in the treatment of neonatal respiratory distress syndrome is effective and worthy of clinical promotion.